Biotech startups that raised Series C in Zhejiang, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| AusperBio | Hangzhou | Series C | $120.0M | 2026-08-27 |
| Healsun Biopharm | Hangzhou | Series C | $27.8M | 2025-11-19 |
| DIAGENS | Hangzhou | Series C | $14.1M | 2023-12-29 |
| LYNK Pharmaceuticals | Hangzhou | Series C | $16.7M | 2023-09-21 |
| Konfoong Biotech International | Ningbo | Series C | $14.9M | 2022-07-12 |
5 rows of the CSV in 5 of its 18 columns.
- The 23 biotech startups in Zhejiang, China whose last round is Series C have raised $1.1B in total.
- 6 of them closed their most recent round in the last 12 months, $221.7M combined.
- The largest of those rounds is AusperBio's $120.0M Series C, dated August 2026.
- Yinxinggu Capital is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 23 companies (100%).
- 4% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 51 to 100 employees (39% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
5 of 23| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Hangzhou | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
| DIAGENS | DIAGENS is a Hangzhou-based biotechnology firm that provides in-vitro diagnostic products and medical equipment. | Biotech | Hangzhou | Series C | $14.1M | 2023-12-29 | Shenzhen Guozhong Venture Capital Management, Haiyuan Capital, China Venture Capital HRVC +2 | 51 to 100 | 2014 | |
| LYNK Pharmaceuticals | LYNK Pharmaceuticals is a biotech company that discovers and develops new medicines. | Biotech | Hangzhou | Series C | $16.7M | 2023-09-21 | Legend Capital, Kaitai Capital, New Alliance Capital +2 | 11 to 50 | 2018 | |
| Konfoong Biotech International | Konfoong Biotech International is a biotechnology company. | Artificial intelligence | Ningbo | Series C | $14.9M | 2022-07-12 | Intel Capital, Yinxinggu Capital | 101 to 250 | 2011 |
Table 1. Biotech startups that raised Series C in Zhejiang, China: the 5 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 23.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, BioVenture, Hankang Capital +1 | 51 to 100 | 2019 |
| 2 | Healsun Biopharm | Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. | Biotech | Hangzhou | Series C | $27.8M | 2025-11-19 | $101.3M | Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 | 251 to 500 | 2015 |
Table 2. Biotech startups that raised Series C in Zhejiang, China: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Yinxinggu Capital | Venture capital firm | Hangzhou, China | 2 | 9% | 1 | Healsun Biopharm |
| 2 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 1 | 4% | 1 | AusperBio |
| 3 | Hankang Capital | Venture capital firm | Shanghai, China | 1 | 4% | 1 | AusperBio |
| 4 | BioVenture | Venture capital firm | Suzhou, China | 1 | 4% | 1 | AusperBio |
| 5 | Genesis Capital | Private equity firm | Central, Hong Kong | 1 | 4% | 1 | AusperBio |
| 6 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | 1 | 4% | 1 | Healsun Biopharm |
| 7 | Haibang Capital | Venture capital firm | Hangzhou, China | 1 | 4% | 1 | Healsun Biopharm |
| 8 | Dongfang Jiafu | Private equity firm | Hangzhou, China | 1 | 4% | 1 | Healsun Biopharm |
| 9 | Haitong Capital | Private equity firm | Lisbon, Portugal | 1 | 4% | 1 | Healsun Biopharm |
| 10 | Prox Ventures | Venture capital firm | Shanghai, China | 1 | 4% | ||
| 11 | Qianhai Fund of Funds | Private equity firm | Shanzhen, China | 1 | 4% | ||
| 12 | CD Capital | Venture capital firm | Shanghai, China | 1 | 4% | ||
| 13 | Puhua Capital | Venture capital firm | Hangzhou, China | 1 | 4% | ||
| 14 | China Venture Capital HRVC | Private equity firm | Nanjing, China | 1 | 4% | ||
| 15 | Shenzhen Guozhong Venture Capital Management | Venture capital firm | Shenzhen, China | 1 | 4% |
Table 3. Biotech startups that raised Series C in Zhejiang, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 23 | 100% | $1.1B |
| Hardware | 1 | 4% | |
| Artificial intelligence | 1 | 4% | |
| Software | 1 | 4% |
Table 4. Biotech startups that raised Series C in Zhejiang, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 23 | 100% | $29.6M |
Table 5. Biotech startups that raised Series C in Zhejiang, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Hangzhou | 20 | 87% |
| Ningbo | 2 | 9% |
| Deqing | 1 | 4% |
Table 6. Biotech startups that raised Series C in Zhejiang, China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| August 2026 | 2 | 33% | $149.6M |
| June 2026 | 2 | 33% | $44.3M |
| December 2025 | 1 | 17% | |
| November 2025 | 1 | 17% | $27.8M |
Table 7. Biotech startups that raised Series C in Zhejiang, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 17% | $193.9M |
| 2025 | 6 | 26% | $167.5M |
| 2024 | 1 | 4% | |
| 2023 | 2 | 9% | $30.8M |
| 2022 | 4 | 17% | $62.3M |
| 2021 | 4 | 17% | $318.2M |
Table 8. Biotech startups that raised Series C in Zhejiang, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 1 | 4% |
| 2015 to 2019 | 9 | 39% |
| 2010 to 2014 | 11 | 48% |
| Before 2010 | 2 | 9% |
Table 9. Biotech startups that raised Series C in Zhejiang, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 3 | 13% |
| 11 to 50 | 6 | 26% |
| 51 to 100 | 9 | 39% |
| 101 to 250 | 2 | 9% |
| 251 to 500 | 2 | 9% |
| 501 to 1,000 | 1 | 4% |
Table 10. Biotech startups that raised Series C in Zhejiang, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C and its headquarters is in Zhejiang, China. On 16 November 2026 that is 23 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 5 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 23 rows: 5 have no round amount, 0 no city and 3 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Zhejiang, China whose last round is Series C are on the list?
- 23, in the file dated 16 November 2026. 6 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 23 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.